Sign in to view content

Port Delivery System With Ranibizumab: Key Outcomes From the Ladder Phase 2 Trial That Supported Archway Phase 3 Study Design

Arshad M. Khanani, MD, MA, FASRS

Video
Published 2019

Arshad M. Khanani, MD

AMD Neovascular Part II Symposium

Related

96-Week Visual and Expanded Anatomical Outcomes of Brolucizumab Versus Aflibercept in Patients With nAMD: Results From HAWK and HARRIER
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2019
The Functional Impact of Fluctuating Retinal Thickness in the IVAN and CATT Trials: A Meta-Analysis
Usha Chakravarthy
Updates from the Field
2019
Pharmacokinetic Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 3 Archway Trial
Peter A. Campochiaro, MD
Updates from the Field
2021

Category: AMD-Neovascular

See more